RecruitingPhase 4NCT07132515
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma
Sponsor
Mansoura University
Enrollment
100 participants
Start Date
Aug 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria1
- Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B
Exclusion Criteria1
- Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding
Interventions
DRUGEnoxaparin, warfarrin, or apixaban
Enoxaparin, warfarrin, or apixaban
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07132515
Related Trials
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
NCT073516691 location
Indicators Affecting PVT Recanalization
NCT074733751 location
Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
NCT074693196 locations
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
NCT050957141 location
Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis
NCT069327831 location